AQW 051

Drug Profile

AQW 051

Alternative Names: AQW-051

Latest Information Update: 05 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antipsychotics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders; Drug-induced dyskinesia

Most Recent Events

  • 06 Aug 2015 Vanda Pharmaceuticals is evaluating potential indications for AQW 051 following in-licensing the product from Novartis
  • 23 Dec 2014 AQW 051 licensed to Vanda Pharmaceuticals worldwide
  • 31 Dec 2013 Novartis completes a phase II trial in Cognition disorders in USA (NCT01730768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top